Spectral Design & Test (SDT) demonstrates High-Capacity SRAM Memory Compilers targeted at advanced process nodes for AI driven edge Devices Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
Surface Oncology initiates clinical trial with antibody discovered using Vaccinex’s ActivMAb® Antibody Discovery Platform ROCHESTER,…
Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones
REDWOOD CITY, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Nasdaq: BMEA), a…
Kiniksa Pharmaceuticals Provides Corporate and Portfolio Update
– ARCALYST® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and…
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones
Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533…
Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766 for the Potential Use in the Treatment of Schizophrenia
CVN766 was well tolerated with no serious adverse events CVN766, which has >1000-fold selectivity for…
Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer
Russel Skibsted 2MB Russell Skibsted, CFO of Alimera Sciences Russell Skibstead Hi-Res Russell Skibsted, CFO…
Rezo Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 09, 2023 (GLOBE NEWSWIRE) — Rezo Therapeutics, a biotechnology company pioneering the…
Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors
-Clinical trial is being conducted at St. James’s University Hospital, United Kingdom, in collaboration with…
PROCEPT BioRobotics Announces Preliminary Fourth Quarter and Fiscal Year 2022 Revenue
PROCEPT BioRobotics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 28,…
Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences,…
Krystal Biotech Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa
NEW PDUFA DATE OF MAY 19, 2023 PITTSBURGH, Jan. 09, 2023 (GLOBE NEWSWIRE) — Krystal…
Hepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive Funding
Approximately $2.9 Million from Sale of Its New Jersey State Net Operating Losses (“NOLs”), Plus…
Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023
MRT-2359 received Fast Track designation from the FDA for the treatment of patients with previously…
Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement
Multiyear Development and Support Agreement Lays the Foundation for the Realization of an Advanced Software…
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
Lonza to support the development and manufacturing of CTIM-76, Context’s CLDN6 x CD3 bispecific antibody…
GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines
GreenLight GreenLight’s mRNA design, formulation and manufacturing expertise is currently applied to research and develop…
BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance
—ORLADEYO preliminary 2022 full year net revenue of $251.6 million (+105 percent y-o-y)— —ORLADEYO net…
IO Biotech Provides Business Update
Independent data monitoring committee recommends that the company’s Phase 3 trial evaluating IO102-IO103 in combination…
BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases
—Company also expanding its discovery platform in complement-mediated diseases, including potent, selective, oral molecules targeting…
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology
Kronos Bio will receive a $20 million upfront payment and could receive up to an…